8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

June 20, 2006 

(Date of the earliest event reported)

Simulations Plus, Inc.

(Exact name of registrant as specified in its charter)

California	000-32046	95-4595609
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

42505 10^th Street West, Lancaster, California 93534

(Address of principal executive offices) (Zip Code)

661-723-7723

Registrant's telephone number, including area code

Item 2.01Results of Operations and Financial Condition

On June 20, 2006, Simulations Plus, Inc., a California corporation (the "Company"), issued a press release reporting preliminary financial results for the fiscal quarter ending May 31, 2006. A copy of the press release hereto is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

Item 8.01Other Events

On June 20, 2006, Simulations Plus, Inc., a California corporation (the "Company"), issued a press release announcing that the company’s CEO will be presenting at the Wall Street Reporter Small-cap Discovery Conference in New York on Wednesday, June 21, 2006. A copy of the Power Point Presentation hereto is attached as Exhibit 99.2 to this current report and is incorporated herein by reference.

This report on Form 8-K (the "Report"), including the disclosures set forth herein, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms "anticipates," "expects," "estimates," "believes" and similar expressions, as they relate to us or our management, are intended to identify such forward-looking statements.

Forward-looking statements in this Report or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission (the "Commission"), reports to the stockholders of Simulations Plus, Inc., a California corporation (the "Company" or "us," "our" or "we") and other publicly available statements issued or released by us involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management's best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Commission, each of which could adversely affect our business and the accuracy of the forward-looking statements contained herein. Our actual results, performance or achievements may differ materially from those expressed or implied by such forward-looking statements.

Item 9.01Financial Statements and Exhibits

(c)      Exhibits

99.1	Press Release dated June 20, 2006.
99.2	Power Point Presentation for the Wall Street Reporter Small-cap Discovery Conference on Wednesday, June 21, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SIMULATIONS PLUS, INC.
Dated: June 20, 2006	By:	/s/ Momoko Beran
		Momoko Beran
		Chief Financial Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release dated June 20, 2006.
99.2	Power Point Presentation for the Wall Street Reporter Small-cap Discovery Conference on Wednesday, June 21, 2006.

EX-99.1

Exhibit 99.1

Simulations Plus

Integrating Science and Software

For Further Information:

Simulations Plus, Inc.

42505 10^th Street West

Lancaster, CA 93534-7059

CONTACT:

Investor Relations

Ms. Renée Bouché

Simulations Plus, Inc.

661.723.7723

info@simulations-plus.com

For Immediate Release:

June 20, 2006

Simulations Plus Reports Preliminary Results for Third Fiscal Quarter

Company CEO to Present at Wall Street Reporter Small-Cap Discovery Conference

LANCASTER, CA, June 20, 2006 - Simulations Plus, Inc. (AMEX: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported preliminary financial results for the third fiscal quarter of its 2006 fiscal year ended May 31, 2006, and announced that the company’s CEO will be presenting at the Wall Street Reporter Small-Cap Discovery Conference in New York on Wednesday, June 21, 2006.

Ms. Momoko Beran, chief financial officer of Simulations Plus, stated: “Consolidated revenues for the third quarter were $1,789,000, an increase of 25.6% from $1,424,000 in the third quarter of fiscal year 2005. This is not only a new record for third quarter revenues, but is a record for all quarters when multi-year licenses are recognized ratably (year-by-year rather than up front). Revenues from pharmaceutical software and services were $1,097,000, an increase of 65.7% from $662,000 in the third quarter of fiscal year 2005. Revenues for our Words+ subsidiary decreased 9.2% to $692,000 from $762,000 in the third quarter of fiscal year 2005. Final earnings will not be known until we complete the auditors’ review and tax calculations, but we estimate at this time that earnings for the quarter should be in the range of $0.07-0.11 per share.

“For the first nine months, revenues were $4,089,000, an increase of 16.1% over $3,523,000 for the first nine months of fiscal year 2005. Sales of pharmaceutical software licenses and services in the first nine months were $2,179,000, an increase of 36.5% over $1,596,000 in the first nine months of fiscal year 2005. Words+ sales were $1,910,000, a decrease of 0.8% from $1,926,000 in the previous fiscal year. Again, earnings will not be known for a few more weeks, but we estimate that earnings for the first nine months will be in the range of $0.08-0.12 per share. Cash flow is good and our cash and equivalents at the end of the third quarter exceeded $1 million. The Company remains debt-free.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, noted: “Although it is no longer our practice to provide preliminary results, our decision to do so at this time was due to our participation in Wall Street Reporter’s Small-Cap Discovery Conference and, clearly, we’re very pleased with these preliminary results. In my travels I have been receiving very positive feedback from both large and small customers, with a number of them indicating they plan to increase their number of software licenses and obtain training for additional scientists. The pharmaceutical industry seems to be adopting simulation and modeling software at an accelerating rate. The recent move by Novartis in setting up a separate Simulation and Modeling Department headed by a vice president demonstrates the growing recognition of higher level industry management of the importance of these technologies.”

-more-

About Simulations Plus, Inc.

Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. We have two other businesses that are based on our proprietary technologies: a wholly owned subsidiary, Words+, Inc., which provides assistive technologies to persons with disabilities; and an educational software series for science students in middle and high schools known as FutureLab^™. For more information, visit our Web site at www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 - With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission.

###

EX-99.2

Exhibit 99.2

Simulations Plus, Inc. (AMEX:SLP) Corporate Overview June 21, 2006

With the exception of historical information, the matters discussed in this presentation are forward looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: continuing demand for the Company’s products, competitive factors, the Company’s ability to finance future growth, the Company’s ability to produce and market new products in a timely fashion, the Company’s ability to continue to attract and retain skilled personnel, and the Company’s ability to sustain or improve current levels of productivity. Further information on the Company’s risk factors is contained in the Company’s quarterly and annual reports and filed with the Securities and Exchange Commission. Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

•Simulations Plus, Inc. (AMEX:SLP) - Global business founded 1996 - IPO June 1997 -no further financing to date - Software for pharmaceutical research and development-Consulting studies for pharmaceutical and drug delivery companies - FutureLab simulations for middle-and high-school science (small) •Words+, Inc. -wholly owned subsidiary - Global business founded 1981-Assistive technology products for disabled -Produced augmentative communication system used by Professor Sir Stephen Hawking ("A Brief History of Time") - Technology leader for 25 years - Abbreviate! software for retail market (small)Two Companies

•Simulation and modeling software for pharmaceutical research - ADMET Predictor™-ADMET Modeler™ - ClassPharmer™ - DDDPlus™ - GastroPlus™ -MembranePlus (in development) • Contract services to the pharmaceutical industry-Structure-property modeling-Simulation studies • Troubleshooting problem compounds • Virtual bioequivalence trials • Design of new oral dosage formulations Simulations Plus, Inc.

•Most advanced and widely used simulation of oral absorption and pharmacokinetics - the industry’s “Gold Standard” • Recent addition of physiologically based pharmacokinetics (PBPK)accomplished via 2 ½year collaboration with Hoffmann LaRoche • FDA now has through a Material Transfer Agreement (MTA)GastroPlusTM

•Predicts properties of molecules from just their structures (drawings)•Recently ranked #1 in accuracy for predicting solubility and logP • Outstanding new pKa prediction -complete microspecies equilibria • Seven toxicity models and more in development -new area • >200,000 compounds/hour typical processing speed (2.4 GHz notebook)•Combined use with ClassPharmer provides new sales avenues ADMET PredictorTM

•Effortless creation of artificial neural network ensemble and support vector machine ensemble structure-property models • Improved graphical user interface with unique display of descriptor sensitivities • Speed and model quality unsurpassed -contract studies have shown ability to find useful models from user data (including activity) when others have failed • Seamless coordination with ADMET Predictor -now provided together, and integration into a single package is well along in development ADMET ModelerTM

•Acquired from creditors of Bioreason in November 2005 -merged with ChemTK™ and released as ClassPharmer 4.0 during 2ndquarter -greatly improved speed and flexibility • Helps identify what it is about molecular structure that causes good or bad properties -finds “maximum common substructures” in classes -proprietary algorithms • Combined use with ADMET Predictor is expected to help sell both ClassPharmerTM

•Version 1.0 was not a great seller last year, but afforded the opportunity to get feedback from over 60 industry scientists about what they wanted to see to make it more useful in their jobs•All requested modifications have now been made, as well as the ability to handle new formulations, and version 2.0 was just released•Price is $9,000/year for single-user licenseDDDPlusTM

-Growing team of exceptional scientists and engineers•Chemistry, biochemistry, molecular biology•Chemical engineering, biomedical engineering•Computer science-Recognized world-class expertise in oral drug delivery, pharmacokinetics, pharmacodynamics-Large scale system simulations-Applied numerical simulation/optimization methods to multidimensional nonlinear problems-High quality, rapid structure-property modeling-Marketing and salesto a highly technical global market-Strong relationships with pharmaceutical scientists in industry, government, and academiaCore Capabilities and Strengths

Some of Our International Pharma Customers

3Q Ended 5/31 * 2Q ended 2/28:2006 *2005 2006 2005 Revenues $1.789 * $1.424 $1.48 1.03 Cost of Sales * 0.43 0.39 0.37 Gross Profit * 0.99 1.09 0.66 S,G&A * 0.65 0.69 0.54 R&D * 0.13 0.12 0.13 NIBT 0.32 ~ 0.50 * 0.22 0.30 0.09 Net Earnings 0.26 ~ 0.40 * 0.18 0.25 0.09 Net Earnings per Share $0.07 ~ $0.11* $0.04 $0.0 60.00 Wt’d Average Shares O/S 3.67 * 3.63 3. 67 3.61 * Estimated numbers -subject to review and change at the time of filing with SEC. Selected Income Statement Data (in millions except per share data)

As of May 31, 2006 ASSETS LIABILITIES Cash & cash equivalents $ 1.099* Accounts payable$ 0.160* Accounts receivable 1.572* Accrued expenses 0.361* Other current assets __0.256* Current portion deferred revenue 0.014* TOTAL CURRENT ASSETS__2.927* Other current liabilities 0.012* TOTAL CURRENT LIAB.__0.547* Capitalized software development, net 1.322* Deferred revenue 0.059* Deferred tax asset1.265* TOTAL LIABILITIES__0.606* Other Long-Term assets 0.501* Common stock, $0.001 par value0.004*Additional paid-in capital 5.228* Accumulated retained earnings__0.177* TOTAL shareholders’equity__5.409* TOTAL ASSETS $ 6.015* TOTAL LIABILITIES & EQUITY $ 6.015** Estimated numbers -subject to review and change at the time of filing with SEC. Balance Sheet(in millions)

Revenue History -1,000,000 2,000,000 3,000,000 4,000,000 5,000,000 6,000,000 $ 1998 2000 2002 2004 2006 (9mos) Fiscal Year Revenue Words+Simulations PlusConsolidated

Management & Directors • Walter S. Woltosz , M.S., M.A.S., Chairman & CEO • Momoko A. Beran, B.S., M.B.A., CPA qualified, CFO • Ronald Creeley, B.S., Vice President, Marketing & Sales • Jeffrey A. Dahlen, B.E.E., President, Words+, Inc. • Michael B. Bolger, Ph.D., Director, Life Sciences • Board of directors:-David Z. D’Argenio, Ph.D., Director • Professor and Chairman, Biomedical Engineering, USC-Richard R. Weiss, Ph.D., Director • Formerly, Deputy Director, Launch Systems, U.S. Department of Defense • Formerly, Director, Propulsion, USAF Philips Laboratory-Virginia E. Woltosz, B.S., M.B.A., Director and Secretary • Co-founder, Words+, Inc.

•Emerging, high-growth market•Proprietary multi-platform software•Recurring revenue business model•Fast-growing and profitable•Debt-free•Experienced management team and boardInvestment Highlights